Longeveron (LGVN)

• Market cap: $25.2M
• 1 day: 3.05%
• 5 days: 12.67%
• 1 month: 1.20%
• 3 months: -7.14%
• 6 months: -17.96%
• Year to date: -5.59%
• 1 year: -63.26%
• 5 years: -97.72%
• 10 years: -97.72%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Employees: 25

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

100% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 5

65% more capital invested

Capital invested by funds: $512K [Q3] → $845K (+$332K) [Q4]

21% more funds holding

Funds holding: 19 [Q3] → 23 (+4) [Q4]

1.6% more ownership

Funds ownership: 2.05% [Q3] → 3.65% (+1.6%) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $10 492% upside
• Avg. target: $10 492% upside
• High target: $10 492% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju 34% 1-year accuracy 115 / 343 met price target

492% upside $10

Buy Reiterated

3 Mar 2025